U.S. FDA declines to approve Blueprint"s therapy for type of stomach cancer
U.S. FDA declines to approve Blueprint"s therapy for type of stomach cancer.....»»

FDA declines to approve Daiichi Sankyo"s blood cancer treatment
FDA declines to approve Daiichi Sankyo"s blood cancer treatment.....»»
Biocon#39;s partner Mylan launches first biosimilar of trastuzumab in Australia
Biocon#39;s partner Mylan launches first biosimilar of trastuzumab in Australia.....»»
Analysis: Drugmakers see a pricing blueprint in an $850,000 gene therapy
Analysis: Drugmakers see a pricing blueprint in an $850,000 gene therapy.....»»
Novartis gene therapy approval signals new cancer treatment era
Novartis gene therapy approval signals new cancer treatment era.....»»
Novartis approval for gene therapy signals new cancer treatment era
Novartis approval for gene therapy signals new cancer treatment era.....»»
U.S. FDA declines to review Bristol Myers, bluebird therapy for multiple myeloma
U.S. FDA declines to review Bristol Myers, bluebird therapy for multiple myeloma.....»»
Zydus Cadila launches generic prostate cancer drug at nearly 70% less price in India
Zydus Cadila launches generic prostate cancer drug at nearly 70% less price in India.....»»
U.S. FDA extends review of Bristol Myers" cancer therapy acquired in Celgene deal
U.S. FDA extends review of Bristol Myers" cancer therapy acquired in Celgene deal.....»»
Merck profit rises, cuts 2020 forecast over COVID-19 uncertainty
Merck profit rises, cuts 2020 forecast over COVID-19 uncertainty.....»»
"Waiting game" for Oregon patient needing cancer surgery amid coronavirus
"Waiting game" for Oregon patient needing cancer surgery amid coronavirus.....»»
AstraZeneca"s Imfinzi gets FDA nod to target small-cell lung cancer
AstraZeneca"s Imfinzi gets FDA nod to target small-cell lung cancer.....»»
GIOSTAR Launches Stem Cell / Cancer Research and Therapy Center in Chandigarh, India
GIOSTAR Launches Stem Cell / Cancer Research and Therapy Center in Chandigarh, India.....»»
Biocon and Mylan launch Trastuzumab biosimilar Ogivri in USA
Biocon and Mylan launch Trastuzumab biosimilar Ogivri in USA.....»»
Novartis"s $90 million Swiss factory to help solve cell therapy bottleneck
Novartis"s $90 million Swiss factory to help solve cell therapy bottleneck.....»»
Immunotherapy Emerging as a Treatment of Hope for Those With Lung Cancer
Immunotherapy Emerging as a Treatment of Hope for Those With Lung Cancer.....»»
Housing Absorption Declines 13% in Q2 2019, New Launches Down 2% - ANAROCK
Housing Absorption Declines 13% in Q2 2019, New Launches Down 2% - ANAROCK.....»»
FDA declines to approve Acer Therapeutics" treatment for rare genetic disorder
FDA declines to approve Acer Therapeutics" treatment for rare genetic disorder.....»»
AstraZeneca"s Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
AstraZeneca"s Lynparza gets EU nod as first-line ovarian cancer maintenance treatment.....»»
Over 1.5 crore people will need chemotherapy globally each year by 2040: Study
Over 1.5 crore people will need chemotherapy globally each year by 2040: Study.....»»
Novartis confident of Zolgensma supply, calls $2 million price "speculation"
Novartis confident of Zolgensma supply, calls $2 million price "speculation".....»»